CIZZLE poised to SIZZLE11 Jun 2021 17:46
https://www.proactiveinvestors.co.uk/LON:CIZ/Cizzle-Biotechnology-Holdings-PLC/rns/978889
Allan Syms, Executive Chairman of the Company, said:
"In 2020 we were focussed on completing the acquisition of Cizzle Biotechnology, which I am delighted we completed earlier this month, together with the admission of the Company's shares to trading on the Main Market of the London Stock Exchange.
"Cizzle Biotechnology is developing a blood test for the early detection of lung cancer by detecting a stable plasma biomarker known as CIZ1B. The biomarker is highly correlated with early-stage lung cancer.
"It is known that detecting lung cancer early significantly increases a patients survival prospects. However, this is difficult to do and often requires intrusive follow up testing. This can include repeated CT scanning and/or tissue biopsies, which are both costly to the NHS, health providers and medical insurers and stressful to patients.
"Cizzle Biotechnology's goal is to produce a test that can provide results quickly and accurately and which can lead to better outcomes for lung cancer patients.
"The Directors believe that Cizzle Biotechnology presents a compelling potential value opportunity and has a commercial strategy to develop and gain regulatory approval for the test and engage with potential licencing partners to use its patent protected core technology. We look forward to announcing regular updates on our progress."